BRAF and metastatic melanoma: In patients with BRAF V600 altered metastatic melanoma, are the incremental costs of triplet therapy of atezolizumab, vemurafenib plus cobimetinib vs vemurafenib plus cobimetinib alone cost-effective for the survival gains?